Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies
Summary
Third Opinion Trial Synopsis:
This test is looking at whether a medicine called pembrolizumab can help make tumors smaller in people with a type of cancer called multiple myeloma. These patients either had their cancer come back or did not get better with other treatments. Pembrolizumab is a type of medicine that can help the body's immune system fight off cancer cells, making it harder for them to grow and spread.
This test is looking at whether a medicine called pembrolizumab can help make tumors smaller in people with a type of cancer called multiple myeloma. These patients either had their cancer come back or did not get better with other treatments. Pembrolizumab is a type of medicine that can help the body's immune system fight off cancer cells, making it harder for them to grow and spread.
*Third Opinion AI Generated Synopsis
Trial Summary
This phase II trial tests whether pembrolizumab works to shrink tumors in patients with multiple myeloma whose cancer has come back (relapsed) or did not respond to previous treatment (refractory) with anti-BCMA CAR-T therapies. Immunotherapy with pembrolizumab, may induce changes in body's immune system and may interfere with the ability of cancer cells to grow and spread.
This phase II trial tests whether pembrolizumab works to shrink tumors in patients with multiple myeloma whose cancer has come back (relapsed) or did not respond to previous treatment (refractory) with anti-BCMA CAR-T therapies. Immunotherapy with pembrolizumab, may induce changes in body's immune system and may interfere with the ability of cancer cells to grow and spread.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: